Profile-QSAR and surrogate autoshim protein-family modeling of proteases

Journal of Chemical Information and Modeling

Volumn 52, Issue 9, 2012, Pages 2430-2440

  Mukherjee, Prasenjit ^a   Martin, Eric ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; ENZYMES; ITERATIVE METHODS;

BIOCHEMICAL ASSAY; HIGH THROUGHPUT SCREENING; MEDIUM-THROUGHPUT SCREENING; PREDICTIVE PERFORMANCE; SIMILARITY ANALYSIS; SMALL-MOLECULE DRUGS; STRUCTURAL DIVERSITY; VIRTUAL SCREENING;

AMINO ACIDS;

PEPTIDE HYDROLASE;

ARTICLE; CHEMICAL STRUCTURE; METABOLISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION;

MODELS, MOLECULAR; PEPTIDE HYDROLASES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866707492     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci300059d     Document Type: Article

References (24)

1. Martin, E.; Mukherjee, P.; Sullivan, D.; Jansen, J. Profile-QSAR: A Novel meta-QSAR Method that Combines Activities across the Kinase Family To Accurately Predict Affinity, Selectivity, and Cellular Activity J. Chem. Inf. Model. 2011, 51, 1942-1956
2. Martin, E. J.; Sullivan, D. C. Surrogate AutoShim: Predocking into a Universal Ensemble Kinase Receptor for Three Dimensional Activity Prediction, Very Quickly, without a Crystal Structure J. Chem. Inf. Model. 2008, 48, 873-881
3. Martin, E. J.; Sullivan, D. C. AutoShim: empirically correctedsScoring functions for quantitative docking with a crystal structure and IC50 training data J. Chem. Inf. Model. 2008, 48, 861-872
4. Nazarian, R.; Shi, H.; Wang, Q.; Kong, X.; Koya, R. C.; Lee, H.; Chen, Z.; Lee, M. K.; Attar, N.; Sazegar, H.; Chodon, T.; Nelson, S. F.; McArthur, G.; Sosman, J. A.; Ribas, A.; Lo, R. S. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 2010, 468, 973-977
5. Solit, D. B.; Rosen, N. Resistance to BRAF inhibition in melanomas N. Engl. J. Med. 2011, 364, 772-774
6. Shi, H.; Kong, X.; Ribas, A.; Lo, R. S. Combinatorial Treatments That Overcome PDGFR.beta.-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition Cancer Res. 2011, 71, 5067-5074
7. Liao, J. J.-L. Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors J. Med. Chem. 2007, 50, 409-424
8. Rawlings, N. D.; Barrett, A. J. Evolutionary families of peptidases Biochem. J. 1993, 290, 205-218
9. Rawlings, N. D.; Tolle, D. P.; Barrett, A. J. MEROPS: the peptidase database Nucleic Acids Res. 2004, 32, D160-D164
10. Puente, X. S.; Sanchez, L. M.; Overall, C. M.; Lopez-Otin, C. Human and mouse proteases: A comparative genomic approach Nat. Rev. Genet. 2003, 4, 544-558
11. Drag, M.; Salvesen, G. S. Emerging principles in protease-based drug discovery Nat. Rev. Drug Discovery 2010, 9, 690-701
12. Turk, B. Targeting proteases: successes, failures and future prospects Nat. Rev. Drug Discovery 2006, 5, 785-799
13. Abbenante, G.; Fairlie, D. P. Protease inhibitors in the clinic Med. Chem. 2005, 1, 71-104
14. Acharya, K. R.; Sturrock, E. D.; Rirodan, J. F.; Ehlers, M. R. W. ACE revisited: A new target for structure-based drug design Nat. Rev. Drug Discovery 2003, 2, 891-902
15. De Clercq, E. Antiviral drugs in current clinical use J. Clin. Virol. 2004, 30, 115-133
16. Ruef, J.; Katus, H. A. New antithrombotic drugs on the horizon Expert Opin. Investig. Drugs 2003, 12, 781-797
17. Gustafsson, D.; Bylund, R.; Antonsson, T.; Nilsson, I.; Nystroem, J. E.; Eriksson, U.; Bredberg, U.; Teger-Nilsson, A. C. Case history: A new oral anticoagulant: the 50-year challenge Nat. Rev. Drug Discovery 2004, 3, 649-659
18. Overall, C. M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era Nat. Rev. Cancer 2002, 2, 657-672
19. Powers, J. C.; Asgian, J. L.; Ekici, O. D.; James, K. E. Irreversible inhibitors of serine, cysteine, and threonine proteases Chem. Rev. 2002, 102, 4639-4750
20. Hedstrom, L. Serine Protease Mechanism and Specificity Chem. Rev. 2002, 102, 4501-4523
21. http://en.wikipedia.org/wiki/Naive-Bayes-classifier (accessed 3/1/ 2011).
22. Pipeline Pilot v 8.0 data modeling user guide; 2011.
23. Bemis, G. W.; Murcko, M. A. Properties of Known Drugs. 2. Side Chains J. Med. Chem. 1999, 42, 5095-5099
24. Bemis, G. W.; Murcko, M. A. The Properties of K5nown Drugs. 1. Molecular Frameworks J. Med. Chem. 1996, 39, 2887-2893